of studies on discontinuation, dose reduction and/or spacing of bDMARDs have been performed, but there have been few reports on increased spacing time between tocilizumab (TCZ) administrations so far.

Objectives: To analyze the efficacy of spacing of the intravenous (IV) administration of TCZ in patients with RA.

Methods: 63 patients (11 M, 52 F) who were administered IV TCZ for more than 1 year were enrolled. Eleven patients had shifted to subcutaneous injection and the data at the last IV infusion were analyzed.

Results: Mean age was 57.4 years old (30–78), mean body weight was 55.5 kg (37–85.5), mean duration of illness was 10.7 yrs (0–32). The number of the bDMARDs previously administered were 0.9 (0–3), and duration of TCZ treatment was 46.9 months (13–83). The intervals between administrations were 4 weeks: 28.6%, 5 weeks: 38.1%, 6 weeks: 17.5%, 7 weeks: 6.0%, 8 weeks: 7.9%, and 10 weeks: 1.6%. Tender joint count, swollen joint count, erythrocyte sedimentation rate (ESR), C-reactive protein, matrix metalloproteinase-3 (MMP-3), patient's visual analogue scale (VAS), doctor's VAS, disease activity score (DAS) 28-ESR, simplified disease activity index (SDAI), clinical DAI (CDAI) were significantly improved. All of patients remission rates were 90.5% for DAS28-ESR, 44.4% for CDAI, and 42.9% for SDAI. Patients with prednisolone (PSL) decreased from 50 to 38 ($p=0.031$), at doses of 5.3 (2–10) to 2.7 (0.5–5) mg/day ($p<0.0001$). Patients with methotrexate (MTX) decreased from 46 to 32 patients ($p=0.017$), at doses of 8.1 (2–18) to 6.6 (2–14) mg/weeks ($p<0.0001$). There were no changes in the usage of other csDMARDs. The remission rates of the patients with increased spacing ($n=45$) were 75.6% for DAS28-ESR, 28.9% for CDAI, and 35.6% for SDAI. In 45 patients with increased spacing, both PSL and MTX were significantly reduced even after spacing (2.9: 0.5–5.5 to 2.6: 1–7.0) mg/day, and (6.45: 2–10 to 5.2: 2–12) mg/ weeks, respectively ($p=0.0013$, $p=0.0085$). At the introduction of TCZ, there was no difference in the serum levels of MMP-3 in patients with increased spacing and without spacing 274.8 (24–1310) ng/ml vs 283.3 (32–626) ng/ml $p=0.692$. Serum levels of MMP-3 at the first time of increased spacing were significantly lower in the patients with increased spacing than those at the final point of patients without spacing 72.0 (22.2–236.0) ng/ml vs 165.8 (35.8–619.0) ng/ml, $p=0.000752$. The number of patients with normal levels of MMP-3 among the patients with increased spacing were 25/45 (55.6%) with significantly higher levels for those patients who had no spacing 3/18 (16.7%, $p=0.00567$).

Conclusions: TCZ treatment was associated with significantly reduced disease activity and reduced use of PSL and MTX. Increased spacing between administrations was used in 71.4% of the patients. TCZ was able to reduce PSL and MTX even after spacing. MMP-3 might be a useful marker to decide the spacing period. TCZ is the most inexpensive bDMARD in Japan, but with increased spacing, it is possible to reduce the cost even further with acceptable control of RA symptoms.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.2335

SAT0215 CHARACTERISTICS OF PATIENTS WITH ANKYLOSING SPONDYLITIS, RHEUMATOID AND PSORIATIC ARTHRITIS IN TREATMENT WITH BIOLOGICS IN VERONA'S COHORT: RESULTS FROM VENETO'S REGION BIOLOGICS REGISTER

S. Troplini, O. Viapiana, E. Fracassi, A. Carletto, L. Idolazzi, G. Orsolini, A. Giollo, M. Rossini. *Rheumatology Unit, University of Verona, Verona, Italy*

Background: Since 2013, in Veneto's Region, data registration is mandatory for all patients affected by Rheumatoid arthritis (RA), Psoriatic Arthritis (PA), Ankylosing Spondylitis (AS) in treatment with biologic agents. The biologic DMARDs currently marketed in Italy are: anti-TNF (originator and biosimilar infliximab, etanercept, adalimumab, certolizumab and golimumab), anti-IL6 (tocilizumab), anti-CD20 (rituximab), CTLA-4 like (abatacept) and anti IL-12/23 (ustekinumab).

Objectives: The aim of this study was first to describe the characteristics of patients with RA, PA, AS under biologics and then, to extract and analyze real-life data regarding rheumatic treatments in Verona's cohort.

Methods: The study has been carried out on behalf of Regione del Veneto, Giunta regionale- Ricerca Sanitaria Finalizzata-Venezia-Italy. Data used for analysis were retrieved from Veneto's Region Biologics Register (VRBR). VRBR provides that core variables such as onset and type of disease, anthropometric characteristics (age, sex, body weight, height) are registered at the beginning. Furthermore, prior and concomitant rheumatic treatment (conventional and biologic DMARDs, corticosteroids, NSAIDs), disease activity indicators (DAS 28-PCR, ASDAS-PCR, pain-NRS), prognostic factors (positivity for rheumatoid factor and/or anti-citrulline antibodies in AR, presence of radiological erosions) were assembled at baseline, every 6 months and at the time of biologic's switch or swap.

Results: A total of 983 patients under biologics were examined; 543 (55.2%) with AR, 272 (27.7%) with AP and 168 (17.1%). Between these, 262 (27.2%) patients were naïve to biologics, 128 with AR, 84 with AP, 50 with SA. Mean duration of disease was of 15.3, 10.7 and 12.6 years respectively for RA, PA and AS. Radiological erosions were present in 73% of RA-patients and the percentage was higher in those with positivity for rheumatoid factor and/or anti-citrulline antibodies (84.4% versus 56.2%). More than half of the patients in this cohort were treated at least with one biologic agent; anti-TNFs were the main biologic used (RA:54.8%, PA:92.7%, AS: 100%) followed by Abatacept (25.4%), tocilizumab (12.3%) and rituximab (5.9%) in patients with RA. Methotrexate (MTX) was the prevalent associated c-DMARDs (41.8% in RA and 34.2% in PA) with

mean dose of 11.9 mg/week in RA and 12.1 mg/week in PA. The optimal dose of methotrexate was not achieved prevalently because of drug intolerance.

Conclusions: Profile of both conventional and biological DMARDs looks very different according to the type of rheumatic disease. The first data show an underuse of MTX in patients with RA and PA under biologics with a low mean dosage due to intolerance. Next step is to evaluate long-term outcomes in clinical practice.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.5718

SAT0216 ABATACEPT EXPERIENCE IN BIOLOGIC NAIVE RHEUMATOID ARTHRITIS PATIENTS: HUR-BIO REAL LIFE RESULTS

A. Sari, B. Armagan, L. Kilic, A. Erden, O. Karadag, A. Akdogan, S. Apras Bilgen, S. Kiraz, U. Kalyoncu, I. Ertenli. *Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey*

Background: Abatacept (ABA), a T lymphocyte blocker, is one of the treatment options in rheumatoid arthritis (RA) patients who are resistant to initial therapy with non-biologic disease modifying drugs (DMARDs).

Objectives: Aim of this study was to evaluate the effectiveness, safety and drug survival rates of ABA in RA patients registered in HUR-BIO (Hacettepe University Rheumatology Biologic Registry) database.

Methods: HUR-BIO is a prospective, single center database of biological treatments including 1229 RA patients by August 2016. In total, 247 of patients had received ABA and in 175 (71%) of them ABA was the first biological agent. In this analysis, 158 patients were evaluated due to lack of first follow-up visit in 17 patients. Demographics, clinical and serological data were evaluated. DAS-28 and HAQ-DI scores before ABA and last follow-up visit were also assessed. Kaplan-Meier analysis was used to estimate drug survival rates.

Results: Among 175 (82% female) patients, mean age was 53.6 ± 11.3 and mean disease duration was 10.3 ± 7.3 . Seropositivity for RF and/or ACPA was present in 74.8% of patients. Table 1 represents DAS-28 scores of patients before ABA and last follow-up visit. Mean duration from ABA initiation to first and last follow-up visit was 4.5 ± 3.1 and 15.1 ± 10.2 months, respectively. Female gender was found as a risk factor in terms of remaining of DAS-28 above 3.2 at first control [OR 5.63 (95% CI 1.72–18.41)]. In first follow-up visit, improvement in DAS-28 score of ≥ 1.2 from baseline was more frequent in ACPA positive patients (48/62 (77.4%) vs 17/33 (51.5%), $p=0.01$). HAQ score of > 1.0 was observed in 57.8%, 36.3% and 26.1% of patients at baseline, first follow-up visit and last follow-up visit, respectively. ABA had been ceased in 60 (38.0%) patients during follow-up. The reason for ABA withdrawal was primary unresponsiveness in 22 (36.6%) patients and infection in 2 (3.3%) patients. Drug survival for ABA was shown in Figure 1. Log-rank between RF positive and negative patients was found as 0.067.

Table 1. DAS-28 scores at first and last follow-up visits

	First control visit (n=136)	Last control visit (n=136)
Follow up duration, mean (SD)	4.5 (3.1)	12.3 (10.9)
DAS-28 > 5.1 , n (%)	11 (8.2)	16 (11.8)
DAS-28=3.2–5.1, n (%)	56 (41.8)	46 (33.8)
DAS-28=2.6–3.2, n (%)	23 (17.2)	23 (16.9)
DAS-28 < 2.6 , n (%)	44 (32.8)	51 (37.5)
Remission or low disease activity among patients with at least one follow-up visit, n (%)	67 (50.0)	74 (54.4)
Remission or low disease activity among all patients, n (%) (The worst scenario)	67/158 (42.4)	74/158 (46.8)

Figure 1. ABA survival rates in RF positive and negative patients

Conclusions: In our database, 70% of RA patients received ABA were biologic naïve. Remission or low-disease activity was achieved approximately 50% of patients in first follow-up visit with an average of 4.5 months after beginning of the treatment. Functional improvement was observed in two thirds of patients.